Table 2.
Effective mitocan-based drug combinations ranked in order of decreasing selectivity.
| Rank | Drug combination | Difference in survival between PBMC and MOLM-13, % | Difference in survival between PBMC and OCI-AML2, % | Average difference in survivala, MOLM-13, OCI-AML2, % | Doses of drug1/drug2, corresponding to maximal selectivity |
|---|---|---|---|---|---|
| 1. | IACS/VIN | 80.0 | 80.5 | 80.3 | IACS 25 μM/VIN 10 μM |
| 2. | RT/2-DG | 45.8 | 66.6 | 56.2 | RT 50 μM/2-DG 50 mM |
| 3. | CCCP/DAS | 59.7 | 50.5 | 55.1 | CCCP 200 μM/DAS 50 μM |
| 4. | ABT-199/LND | 51.5 | 49.8 | 50.7 | ABT-199 1.3 μM/LND 50 μM |
| 5. | IACS/2-DG | 38.3 | 53.6 | 45.9 | IACS 50 μM/2-DG 50 mM |
| 6. | RT/VIN | 75.7 | 15.9 | 45.8 | RT 6.3 μM/VIN 5 μM |
| 7. | RT/MID | 51.5 | 32.6 | 42.0 | RT 12.5 μM/MID 1.3 μM |
| 8. | CCCP/2-DG | 55.8 | 16.9 | 36.4 | CCCP 200 μM/2-DG 50 mM |
| 9. | ABT-199/3-BP | 41.9 | 29.6 | 35.8 | ABT-199 1.3 μM/3-BP 12.5 μM |
| 10. | ET/LND | 13.5 | 56.5 | 35.0 | ET 25 μM/LND 100 μM |
| 11. | RT/DAS | 33.4 | 35.5 | 34.5 | RT 12.5 μM/DAS 50 μM |
| 12. | Ara-C/MID | 23.3 | 44.4 | 33.8 | Ara-C 50 μM/MID 10 μM |
| 13. | IACS/DAS | 25.2 | 41.9 | 33.5 | IACS 25 μM/DAS 50 μM |
| 14. | ET/DAS | 32.9 | 31.4 | 32.2 | ET 50 μM/DAS 50 μM |
| 15. | ABT-199/VIN | 20.0 | 40.7 | 30.3 | ABT-199 10 μM/VIN 10 μM |
| 16. | CCCP/LND | 23.8 | 26.4 | 25.1 | CCCP 200 μM/LND 200 μM |
| 17. | RT/LND | 36.1 | 12.5 | 24.3 | RT 12.5 μM/LND 50 μM |
| 18. | ABT-199/3-BP | 19.9 | 23.0 | 21.4 | ABT-199 10 μM/3-BP 5 μM |
| 19. | IACS/MID | 27.1 | 13.8 | 20.5 | IACS 12.5 μM/MID 2.5 μM |
| 20. | ABT-199/2-DG | 22.6 | 8.4 | 15.5 | ABT-199 1.3 μM/2-DG 25 mM |
| 21. | CCCP/3-BP | 13.3 | 7.0 | 10.1 | CCCP 200 μM/3-BP 5 μM |
| 22. | RT/3-BP | NS; Not selective |
a
Maximal difference in survival between normal PBMC and AML (average for MOLM-13 and OCI-AML2 cells), %. Data from all biological replicates (n = 3) were combined.
Combinations chosen for further studies (average maximal difference in survival >50%) are in bold.
NS, non-significant difference in survival between normal PBMC and AML (MOLM-13/OCI-AML2) cells.
Not selective, significantly lower survival of normal PBMCs (not selective combination).